Heidelberg Pharma AG Stock
Heidelberg Pharma AG Stock
Heidelberg Pharma AG gained 0.780% compared to yesterday.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Heidelberg Pharma AG stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Heidelberg Pharma AG in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Heidelberg Pharma AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Heidelberg Pharma AG | 0.780% | 0.784% | -1.533% | -38.955% | 6.639% | -27.809% | -62.861% |
| Vivoryon Therapeutics N.V. | 0.850% | 0.862% | 7.339% | -16.667% | -19.087% | -90.625% | -93.881% |
| Nanorepro AG | 1.000% | -5.189% | -6.075% | 32.237% | 33.555% | -11.454% | -65.404% |
| Larimar Therapeutics Inc. | -1.740% | -3.550% | 15.603% | 10.135% | -1.807% | -6.857% | -60.958% |
Comments
systinvest bought the security Heidelberg Pharma AG in his wikifolio Aktienwertselektion mit System.
Show more
News
EQS-News: Heidelberg Pharma Reports on First Half-Year 2026 and the Positive Course of Business
EQS-News: Heidelberg Pharma Reports on First Half-Year 2026 and the Positive Course of Business
EQS-News: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2026
EQS-News: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2026
EQS-News: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2026
EQS-News: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2026